ReviewBioengineering & translational medicine2025
Biosynthetic blood surrogates: Current status and future opportunities.
Review in Bioengineering & translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Novel therapies for von Willebrand disease.Blood advances · 2026Review
- Lyophilized Synthetic Platelets: In Vitro Characterization and In Vivo Evaluation in Mouse Thrombocytopenia Model.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- Biosynthetic blood surrogates: Current status and future opportunities.Bioengineering & translational medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Blood is a liquid connective tissue containing cellular and non-cellular components. Blood circulation is vital to life since it transports gases and nutrients, maintains immune surveillance, promotes necessary clotting to prevent hemorrhage, and maintains oncotic pressure and body temperature. Blood transfusion is a life-saving procedure where donor-derived blood is administered into a patient when the patient's own blood is diseased or depleted. However, blood transfusion faces tremendous challenges due to donor shortage, limited shelf life, transfusion-associated infection risks, and complex logistics of blood banking and transport. A robust volume of research is currently focused on resolving these issues, including pathogen reduction technologies, temperature-reduced storage, and bioreactor-based production of blood cells from stem cells in vitro. In parallel, significant interest has developed toward biomaterials-based engineering of synthetic blood surrogates that can provide critical functions of blood components while circumventing the limitations of donor-derived blood products. Here, the major efforts have focused on the design of RBC surrogates for oxygen transport and platelet surrogates for hemostatic functions, and only limited efforts have focused on WBC mimicry. Processes have also been developed to isolate plasma or coagulation factors to treat specific bleeding risks, as well as freeze-dry or spray-dry plasma for long-term storage and on-demand use. The current article will provide a comprehensive review of various blood surrogate approaches highlighting biomaterials design and applications, important challenges, and future opportunities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.